SOUTH SAN FRANCISCO, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that Phase 3 clinical data and preclinical data from studies of the Company’s Factor Xa inhibitor antidote AndexXaTM (andexanet alfa) will be presented in poster sessions at the upcoming 14th Annual Neurocritical Care Society Meeting, which will take place from September 15-18 in National Harbor, Md. Additionally, results of a retrospective chart review on treatment patterns and outcomes of patients receiving oral Factor Xa inhibitors who experienced life-threatening intracranial hemorrhage (ICH) will be presented in a poster session.
AndexXa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, is in development for patients treated with a direct (apixaban, rivaroxaban, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Currently, there is no FDA-approved antidote to reverse the anticoagulant activity of Factor X inhibitors. Portola is committed to conducting and supporting research to understand the real-world management, outcomes and resource utilization of Factor Xa inhibitor-associated major bleeding in order to improve morbidity and mortality in these patients.
The abstracts are now available at http://www.neurocriticalcare.org/Meetings/2016-Annual-Meeting/2016-Abstract-Submission-and-Poster-Information. Following are details of the poster presentations, which will take place in Prince George Exhibit Hall A of the Gaylord National Resort and Convention Center. The posters will include additional data not available in the posted abstracts.
AndexXa Poster Presentations
Retrospective Chart Review Poster Presentation
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.GlobeNewswire
Last updated on: 14/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.